Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Janux Therapeutics Inc (JANX) and CVS Health (CVS)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Gilead Sciences (GILD – Research Report), Janux Therapeutics Inc (JANX – Research Report) and CVS Health (CVS – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Gilead Sciences (GILD)
J.P. Morgan analyst Chris Schott maintained a Buy rating on Gilead Sciences yesterday. The company’s shares closed last Monday at $149.83.
According to TipRanks.com, Schott is a 4-star analyst with an average return of
Gilead Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $155.39, which is a 4.3% upside from current levels. In a report issued on February 10, UBS also maintained a Buy rating on the stock with a $155.00 price target.
See the top stocks recommended by analysts >>
Janux Therapeutics Inc (JANX)
In a report released today, Karina Rabayeva from Truist Financial maintained a Buy rating on Janux Therapeutics Inc. The company’s shares closed last Monday at $13.37.
According to TipRanks.com, Rabayeva is ranked #11073 out of 12136 analysts.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Janux Therapeutics Inc with a $52.00 average price target, representing a 299.1% upside. In a report issued on February 17, William Blair also maintained a Buy rating on the stock.
CVS Health (CVS)
Deutsche Bank analyst George Hill maintained a Buy rating on CVS Health on February 20. The company’s shares closed last Monday at $77.00, close to its 52-week high of $80.75.
According to TipRanks.com, Hill is a 4-star analyst with an average return of
CVS Health has an analyst consensus of Strong Buy, with a price target consensus of $96.24, implying a 26.6% upside from current levels. In a report issued on February 10, TD Cowen also maintained a Buy rating on the stock with a $105.00 price target.
